PDS Biotechnology Corporation reported a net loss of $9.0 million, or $0.19 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $10.7 million, or $0.29 per basic and diluted share, for the same period in 2024. Research and development expenses were $4.6 million, down from $6.8 million in the prior year period, primarily due to lower manufacturing, clinical expenses, and personnel costs. General and administrative expenses were $3.6 million, up from $3.4 million, mainly due to higher professional fees. Total operating expenses decreased to $8.1 million from $10.2 million. Net interest expense increased to $0.9 million from $0.5 million, largely due to lower interest income. During the quarter, the company completed the VERSATILE-002 Phase 2 trial of PDS0101 with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer and announced plans to seek an expedited approval pathway for the ongoing VERSATILE-003 Phase 3 trial.